康龍化成(300759.SZ):擬1億元參與投資寧波甬康股權投資合夥企業
格隆匯3月19日丨康龍化成(300759.SZ)公佈,為充分運用專業投資機構在行業內投資、研判的能力,提高公司投資能力,同時促進寧波醫藥行業的高質量發展,公司擬作為有限合夥人以自有資金認繳出資10,000萬元人民幣參與投資寧波甬康股權投資合夥企業(有限合夥)(暫擬名稱,以市場監督管理機關核定的名稱為準,稱“基金”或“合夥企業”)。2025年3月19日,公司簽署了《關於寧波甬康股權投資合夥企業(有限合夥)(擬)之有限合夥協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.